What medicine is Rytelo (Imetelstat)?

Rytelo (Imetelstat) is an oligonucleotide telomerase inhibitor classified as an anticancer drug indicated for the treatment of adult patients with low-to-moderate risk myelodysplastic syndrome (MDS) who have transfusion-dependent anemia who require 4 or more red blood cell units for more than 8 weeks and are unresponsive or ineligible for an erythropoiesis-stimulating agent (ESA).

Myelodysplastic syndromes are a group of diseases caused by bone marrow stem cell dysfunction. One of its main symptoms is insufficient red blood cell production, which leads to anemia. Therefore, these patients require regular blood transfusions to maintain normal hemoglobin levels. Imetelstat, the active ingredient in Rytelo, selectively targets malignant stem cells and progenitor cells in the bone marrow by binding to and inhibiting the activity of telomerase, thereby reducing the number of these abnormal cells and improving transfusion-dependent anemia in patients with myelodysplastic syndrome.

When using Rytelo, the recommended dose is 7.1mg/kg calculated based on the patient's weight, via intravenous infusion for 2 hours every 4 weeks. The dosage and dosage regimen should be determined based on the patient's actual condition and the doctor's recommendations, and needs to monitor the patient's therapeutic effects and adverse reactions. Some adverse reactions may occur during the use ofRytelo. The most common ones include thrombocytopenia, leukopenia, neutropenia, elevated aspartate aminotransferase, elevated alkaline phosphatase, elevated alanine aminotransferase, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infection, and headache. These adverse reactions need to be monitored and managed according to the patient's condition.